Eurax

Selected form

Crotamiton

Method of action: Antiparasitic, Antipruritic, Anti-Scratch, Ectoparasiticides, Incl. Scabicides, Insecticides And Repellents, Other Dermatological Preparations

Treatment option: Chickenpox, Rash, Dermatitis, Sunburn, Jock Itch, Hives, Insect Bite Or Sting, Scabies, Eczema

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eurax

What is Eurax? (Crotamiton)

Property	Description
Active ingredient	Crotamiton (10%)
Form	Cream or Lotion (Topical preparation)
Pharmacological class	Scabicidal Agent, Antipruritic Agent
Common use	Dual action for parasitic infestation and itching relief
Origin	Synthetic Compound

Eurax is a synthetic, topical dermatological agent primarily used on the skin, distinguished by its established dual pharmacological action as both an agent for parasite elimination and a medication for symptomatic itching relief.

1. Active Ingredient and Dermatological Identity

The preparation's single active component is Crotamiton (INN), a non-steroidal, synthetic chemical compound formulated exclusively for cutaneous administration (external application to the skin). Crotamiton is typically supplied as a 10% concentration in semisolid dosage forms, either a cream or a lotion base, which offers differing cosmetic properties for patient preference and skin condition. Its status as a single-ingredient topical agent positions it distinctly from combination products used in the dermatological field.

2. Dual Pharmacological Classification

Crotamiton is officially categorized within two distinct pharmacological groups: it functions as a scabicidal agent (or acaricide) and concurrently as an antipruritic agent (anti-itch agent). This dual categorization reflects its two separate actions. The acaricidal role involves a specific neurotoxic effect that targets arthropod parasites. Separately, Crotamiton's antipruritic function provides a direct benefit by influencing peripheral nerve endings in the skin, which helps to mitigate the sensation of intense itching that often accompanies skin conditions.

3. General Purpose of Crotamiton

The fundamental utility of this medication is to provide a comprehensive, two-pronged response to skin conditions characterized by parasitic activity and severe pruritus. The core purpose of applying Crotamiton is to achieve the simultaneous goals of eradicating the parasitic source of skin irritation and alleviating the associated, persistent itching. This inherent ability to deliver both parasitic control and symptomatic relief distinguishes Crotamiton, making it a recognized choice for situations where intense itching accompanies the need for parasitic eradication.

What side effects are possible with Eurax?

Possible Side Effects and Safety Information

This information describes the possible side effects and safety considerations for Eurax (Crotamiton) as documented in official government regulatory sources.

Adverse Reactions by Frequency

The majority of reported adverse reactions are local and affect the skin. These effects are classified according to frequency found in regulatory documents:

Frequency Classification	Side Effects
Uncommon (Affects 1 to 10 users in 1,000)	Pruritus (itching), skin irritation.
Rare (Affects 1 to 10 users in 10,000)	Hypersensitivity reactions.
Frequency Not Known (Cannot be estimated)	Contact dermatitis, erythema (redness), eczema, angioedema (swelling), urticaria (hives).

Serious Safety Considerations

Official documents note the potential for serious adverse reactions, primarily within the class of Immune System Disorders. These include hypersensitivity reactions, which may manifest as severe allergic responses like angioedema, requiring immediate attention.

Safety-Related Restrictions and Limitations

To minimize adverse effects and the risk of the drug being absorbed into the body (systemic absorption), specific application restrictions are mandated in regulatory labeling:

Do not apply near the eyes or to mucous membranes (e.g., mouth, nose, genitals).
Do not use on broken, acutely inflamed, or weeping skin (oozing dermatosis).
The product is contraindicated if a known hypersensitivity exists to Crotamiton or any other ingredient.

Population and Exposure Considerations

Use in infants and children should be supervised by a medical professional, particularly when the product is applied over large skin surfaces. The risk of systemic absorption is noted to increase significantly when the product is applied to extensive skin areas, damaged skin, or under occlusive dressings.

Overdose and Emergency Response

The official regulatory documentation for Crotamiton primarily addresses scenarios of accidental oral ingestion. Manifestations of acute intoxication following ingestion include a burning sensation in the mouth and throat, along with gastrointestinal effects such as nausea, vomiting, and abdominal pain. Regulatory labeling notes potential irritation of the buccal, esophageal, and gastric mucosa.

In rare instances, accidental ingestion has been associated with severe neurological manifestations, including seizures and loss of consciousness. Furthermore, there is a very rare, documented risk of developing methaemoglobinaemia following either ingestion or excessive cutaneous absorption.

When accidental oral ingestion occurs, the regulator-mandated action is to call your Poison Control Center immediately for urgent guidance. Management for acute intoxication involves administering general measures aimed at eliminating the drug and reducing its absorption, followed by appropriate symptomatic treatment. Although no specific antidote for Crotamiton is known, Methylene Blue may be considered by clinicians for severe cases of methaemoglobinaemia. There is no specific official guidance documented regarding the effects of repeated topical overtreatment in humans.

Therapeutic Uses of Eurax

What Eurax Treats: Main Uses and Benefits

The utility of Crotamiton is relevant across domains where additional symptomatic support is needed, assisting with parasitic infestation and symptoms related to physical discomfort. It is generally used to help with the management of scabies infestation and for the symptomatic relief of pruritic skin.

Management of Scabies Infestation and Associated Itching

This medication is commonly applied across conditions associated with acute or disruptive episodes where symptoms related to heightened physiological activity are present. The primary therapeutic domain involves assistance with conditions presenting with systemic or localized discomfort caused by parasites, while concurrently helping to address symptoms that create noticeable physiological strain. It is relevant in scenarios involving conditions presenting with symptomatic discomfort, such as scabies, dry eczema, allergic rashes, hives, or irritation from insect bites and sunburn. This generally contributes to improved comfort during periods of heightened symptoms and may help patients cope more steadily with symptom fluctuations.

Supportive Management for Persistent and Acute Pruritus

The relief component is relevant when supportive symptom management is appropriate for conditions characterized by periods of heightened symptoms. It is relevant for managing symptoms that interfere with daily comfort, and generally assists with maintaining functional stability during symptomatic phases. Crotamiton is also commonly applied in scenarios relevant when supportive symptom management is appropriate after a scabies infestation has been managed, contributing to easing the overall symptom load.

Quick Fact: Support for Symptoms of Itching

Crotamiton is commonly used to help manage both the acute symptoms of itching associated with active parasitic infestation and the persistent itching that may follow the management of the condition.

Regulatory References

NIH DailyMed Labeling for Crotamiton

Eligibility and Restrictions for Use

Who Can and Cannot Use Eurax?

This section describes the population eligibility and restrictions for using Eurax (Crotamiton) according to official government regulatory documentation.

Eligibility Status

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and older adults are the standard eligible groups, with no special dosage recommendations noted for the elderly.
Populations for whom use is contraindicated	Individuals with known hypersensitivity to the active substance, crotamiton, or to any of the product's excipients.
Condition-specific contraindications	The medicine must not be applied to acutely inflamed raw skin, broken skin, raw oozing areas, or areas of acute exudative dermatoses.

Restricted and Special-Consideration Groups

Age Group / Status	Official Regulatory Restriction
Children (General)	Safety and effectiveness have not been established (US labeling).
Children under three years of age	Use is restricted to under medical supervision and should not be applied more than once a day (EU/UK labeling).
Pregnancy	Use is not recommended (EU/UK). The US FDA assigns a Pregnancy Category C; use only if clearly needed.
Lactation	Use is not recommended unless directed by a physician. If used, the cream must not be applied to the nipple area.

These statements formally classify who is permitted to use the medicine under standard conditions and who is restricted or excluded based on age, physiological state, or existing local dermatological status.

What should I know about interactions with other medicines?

The official regulatory profile for Eurax (Crotamiton) interactions is defined by the information provided in authoritative prescribing documentation, such as the Summary of Product Characteristics (SmPC) used by European regulatory agencies. This documentation explicitly states that no dedicated drug-drug interaction studies have been performed for Crotamiton, a topical agent. This regulatory status means that specific interactions with co-administered medicines, foods, or supplements have not been formally identified or documented in official labeling.

Official Regulatory Status of Interactions

Interaction Type	Status in Regulatory Documents
Pharmacokinetic (e.g., CYP Enzymes)	None documented
Pharmacodynamic Effects	None documented
Food or Substance Interactions	None documented
Timing/Separation Rules	None mandated

Since formal studies are absent, the official interaction sections contain no specific list of interacting medicinal products. Furthermore, there are no explicitly classified combinations prohibited due to a known interaction risk, and no mandatory requirements for spacing the administration of Crotamiton with other medicines are established in regulatory documents. The profile contains no population-specific interaction cautions relevant to metabolism or altered systemic exposure.

Mechanism of Action

The pharmacodynamic action of Crotamiton is characterized by a distinctive dual-mechanism approach that influences two entirely separate biological systems: human sensory nerves and the nervous system of external parasites.

Peripheral Sensory Nerve Modulation

This domain covers the drug's effect on pruriceptive signaling in the periphery. Crotamiton engages mechanisms that act directly on voltage-gated sodium channels (Nav channels) of peripheral sensory nerve endings (C-fibers) in the skin. By modulating or blocking these channels, the molecule prevents the sustained influx of sodium ions required to generate and propagate an electrical nerve impulse. This action stabilizes the nerve membrane and dampens the transmission of afferent nerve signals from the skin, leading to a functional consequence of reduced nerve excitability.

Arthropod Neurotoxic Disruption

This mechanism is focused on the parasite's nervous system (e.g., Sarcoptes scabiei mites). Crotamiton exerts a neurotoxic action that rapidly and non-specifically disrupts the parasite's central and motor neural control. This leads to an initial state of motor hyper-excitation and convulsions in the arthropod, swiftly followed by a state of irreversible paralysis and exhaustion. This targeted disruption of the parasite's vital physiological system leads to parasite mortality.

Dosage and Administration Information

How Eurax (Crotamiton) is Used

Crotamiton, formulated as a 10% cream or lotion, is administered strictly via the topical route for application to the skin. It is designated For Topical Use Only and is not to be used orally or in other orifices. The application frequency and technique are defined by the therapeutic purpose: a fixed, two-day course for scabies infestation, and an intermittent, as-needed pattern for symptomatic relief of pruritus.

Administration for Scabies Eradication

Procedural Step	Instruction
Route and Coverage	Apply a thin layer to the entire body from the chin down, thoroughly massaging into the skin.
Frequency	Apply twice: the second application is scheduled 24 hours after the first.
Post-Application Care	A cleansing bath should be taken 48 hours after the second application to remove the medication. Clothing and bedding should be changed the morning after the first application.
Retreatment	The treatment course may be repeated after 7 to 10 days only if live mites are observed.

Usage for Symptomatic Pruritus Relief

For general itching, the preparation is massaged gently into the affected areas until it is completely absorbed. This application is repeated as needed to relieve symptoms.

Administration Constraints and Population Notes

The preparation must not be applied to skin that is acutely inflamed, raw, or weeping. The safety and effectiveness in children have not been established. These instructions define the standardized approach to using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eurax (Crotamiton)

Evidence for the Scabicidal Action

The primary research for Crotamiton has centered on studies exploring the product in the context of active parasitic infestation, specifically scabies. The evidence base includes Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that analyze and compare topical preparations. These studies were used in research exploring measures of parasite presence, often referred to as the 'cure rate', with observation periods typically lasting up to four weeks.

Research populations have included individuals spanning different age ranges, including adults and children. The published literature describes the range of measured endpoints related to parasite presence that were observed in trials. The evidence is broadly categorized as Moderate, but scientific summaries note that findings were mixed in some head-to-head comparisons. Study limitations include modest sample sizes in some older trials and limited follow-up duration for assessing long-term recurrence.

Evidence for the Antipruritic Action

Crotamiton was studied for its application in the context of symptomatic pruritus, or itching. The evidence relies on smaller, older clinical trials and supporting observational data. These trials primarily focused on measuring changes in the intensity of the itch and the duration of those changes, using patient-reported outcomes.

Findings describe patterns observed in the studies over the course of hours or days following application. However, certainty remains low for this application. Some controlled trials documented instances where the measured changes in symptoms were not substantially different from the changes reported by patients using the inactive cream base alone. The evidence level is broadly categorized as Low, and the lack of recent, large-scale, placebo-controlled data highlights an area where data are still emerging.

Key Studies & References

Label: CROTAN- crotamiton lotion (FDA/DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Eurax (FAQ)

Q: Is Eurax the same as hydrocortisone cream?

Eurax (Crotamiton) is officially classified as a scabicidal agent and an antipruritic agent. Official regulatory documents indicate that it is a non-steroidal, synthetic compound. This classification distinguishes it from corticosteroid creams, such as hydrocortisone.

Q: Does Eurax help with general skin itching?

The official approved indications for Crotamiton include the symptomatic treatment of pruritic skin, which refers to general itching. It is also approved for the eradication of scabies.

Q: Can Eurax be used on the face?

Regulatory documents advise against application near the eyes or to mucous membranes (like the inside of the nose or mouth) due to safety precautions. Official documentation does not provide explicit guidance or restriction for other areas of the face.

Q: Can I use Eurax if I have other skin conditions like psoriasis?

Official documents do not list chronic skin conditions such as psoriasis as a specific contraindication. However, the medicine must not be applied to any area of skin that is acutely inflamed, raw, broken, or weeping (oozing dermatosis), which may occur with certain skin conditions.

Q: Does Eurax work by numbing the skin?

The mechanism of action is described in official documents as acting on peripheral sensory nerve endings in the skin. This action helps to modulate ion channels to reduce nerve excitability and dampen the transmission of nerve signals that cause itching.

Q: How long does it take for Eurax to start working for itching?

Studies on the product’s anti-itch effect primarily focused on measuring changes in the intensity of symptoms over a course of hours or days following application.

Q: Can Eurax be used for insect bites?

Insect bites are not listed as a specific approved indication. The official approved uses for the medicine are the symptomatic treatment of pruritic skin (itching) and the eradication of scabies.

Q: Is Eurax available over the counter or is it prescription only?

Official regulatory documents generally designate Crotamiton as a prescription-only product.

Q: Do I need to wash Eurax off after a certain time?

Regulatory instructions for using the medicine for general itching state that application should be repeated as needed to relieve symptoms, with no specific post-application washing requirement noted for this purpose. Washing is only mandated as part of the scabies protocol.

Q: What happens if I use Eurax more often than directed on the label?

Regulatory documents note that the risk of the drug being absorbed into the body (systemic absorption) increases significantly when applied over extensive skin areas, damaged skin, or under occlusive (airtight) dressings. It is described as for topical use only.

Q: Will Eurax help with itching from eczema?

Eczema is not listed as a specific approved indication in regulatory documents. The official approved uses for the medicine are the symptomatic treatment of pruritic skin (itching) and the eradication of scabies.

Q: Are there different strengths or formulations of Eurax?

Crotamiton is typically supplied as a 10% concentration. This strength is available in topical dosage forms, specifically as a cream or a lotion base.

Q: Can I use Eurax if I have a known allergy to other topical medications?

Official prescribing information indicates that the medicine should not be used if a known hypersensitivity exists to the active substance (Crotamiton) or any of the product's excipients. Regulatory documents also note that a sensitivity to other topical medications may be relevant.

Q: What happens if I miss a scheduled application of Eurax?

For the fixed-schedule scabies application, official guidance addresses what to do for a missed dose, recommending that the regular schedule should be followed if the next application time is approaching.

Q: Does Eurax contain antihistamines?

The active ingredient in Eurax is Crotamiton, which is classified as an antipruritic agent and is not an antihistamine. Its mechanism of action for itching relief is different from that of antihistamine medicines.

Q: What should I do if I accidentally swallow a small amount of Eurax?

The medicine is strictly for topical use only. Official information warns that the medicine may be harmful if swallowed. If accidental ingestion occurs, official guidance directs contacting a Poison Control Center immediately.

Q: Why does Eurax sometimes cause a burning feeling when I apply it?

Regulatory documents report skin irritation, which may include a feeling of heat or an irritated sensation, as a possible adverse reaction classified as uncommon.

Q: How should Eurax be applied to be most effective?

For symptomatic itching relief, official instructions state the preparation is to be gently massaged into the affected areas until it is completely absorbed. Application should be repeated as needed to relieve symptoms.

How should Eurax be stored and disposed of?

Storage and Disposal of Eurax Cream

Eurax Cream (Crotamiton) must be stored and handled according to the following official requirements to ensure stability and safety:

Official Storage Conditions

Temperature: The medicine must be stored at or below 25 C. US labeling specifies a controlled room temperature range of 20 C to 25 C (68 F to 77 F).
Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.
Stability: The product should not be used after the expiry date on the container and must be used within 12 months of opening.

Handling and Disposal Requirements

Fire Hazard: Fabric, such as clothing or bedding, that has been in contact with Eurax Cream is a serious fire hazard and may ignite easily. This residue may not be completely removed by washing, and the product must be kept away from fire during use.
Disposal: Unused or expired cream must be disposed of according to local regulatory requirements for waste medicinal products. If a take-back program is unavailable, some guidance recommends mixing the product with an undesirable substance for disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.